A study comparing Gilenya Home first dose observation (FDO) findings in patients starting fingolimod with in clinic FDO findings: Gilenya@Home Program
Latest Information Update: 30 Oct 2018
Price :
$35 *
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 12 Oct 2018 Results of FDO findings in younger vs older patients initiating fingolimod at home or in the clinic (n=19,933) presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 12 Oct 2018 Results assessing relationship between baseline heart rate and adverse events presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 21 Nov 2017 New trial record